{"filing":{"accession_number":"0001493152-26-031124","cik":"0000908259","ticker":"OTLC","company_name":"Oncotelic Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226031124/form8-k.htm"},"events":[{"id":14739,"run_id":13131,"accession_number":"0001493152-26-031124","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"Oncotelic Therapeutics completed an unregistered sale of equity securities, including convertible promissory notes, as evidenced by the Securities Purchase Agreement and Convertible Promissory Note exhibits filed with the 8-K. This private placement represents a material capital-raising transaction that dilutes existing shareholders.","company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":12261,"accession_number":"0001493152-26-031124","item_number":"1.01","item_title":", above.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly discloses an unregistered sale of equity securities. This is a classic dilutive issuance event — the sale of equity without registration, typically a private placement or PIPE offering. Such transactions are material to investors as they dilute existing shareholders and signal capital-raising activity, often indicating financial need at smaller issuers like Oncotelic.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T21:16:38.964104+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12261,"accession_number":"0001493152-26-031124","item_number":"1.01","item_title":", above.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly discloses an unregistered sale of equity securities. This is a classic dilutive issuance event — the sale of equity without registration, typically a private placement or PIPE offering. Such transactions are material to investors as they dilute existing shareholders and signal capital-raising activity, often indicating financial need at smaller issuers like Oncotelic.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T21:16:38.964104+00:00","company_name":"Oncotelic Therapeutics, Inc.","ticker":"OTLC","filing_date":"2026-06-29"}]}